Boston Scientific (BSX) slid roughly 3% in Wednesday trading (April 29, 2026), extending a post-earnings decline as the market continues to digest management’s reset of 2026 expectations and the wave of follow-on analyst target reductions. The stock move looks more like continued de-risking after the outlook cut rather than a single new headline on the day.

The company reported first-quarter 2026 results on April 22, 2026, including net sales of about $5.203 billion and adjusted EPS of $0.80, both ahead of typical Street expectations. However, Boston Scientific lowered its full-year 2026 guidance, including reduced expected sales growth and a lower adjusted EPS range—shifting investor focus from the quarter’s beat to a softer trajectory for the remainder of the year.

The guidance reduction was framed around headwinds in several key businesses, with particular investor sensitivity around electrophysiology and WATCHMAN trends. With those franchises viewed as important growth engines, any sign of slower momentum can have an outsized impact on the multiple, especially after the stock’s larger drawdown from prior highs.

In the days following the guidance change, analysts have been trimming price targets and modeling a weaker near-term setup, in some cases calling for the second quarter to represent a trough before growth re-accelerates later in 2026. Investors will likely focus next on whether second-quarter growth stabilizes, whether share trends improve in electrophysiology and WATCHMAN, and whether management can restore confidence in the updated 2026 path.